2024-03-09 04:50:41 ET
Summary
- Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue.
- The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offering and next-gen data platform, are expected to drive growth and margin expansion.
- HCAT's long-term guidance of exceeding $100 million in EBITDA by FY28 is achievable, and its valuation should improve as it demonstrates execution and margin expansion.
Investment action
Read the full article on Seeking Alpha
For further details see:
Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible